Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangxi Traditional Chinese Medical University, Nanning, Guangxi Zhuang Autonomous, Region, 530023, PR China.
Department of Thoracic and Cardiovascular Diseases, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous, Region, 530021, PR China.
Clin Chim Acta. 2017 Nov;474:14-22. doi: 10.1016/j.cca.2017.08.034. Epub 2017 Aug 31.
The impact of miR-10b expression on the survival outcome of patients with cancers is still controversial.
A systematic review and meta-analysis was performed to determine its implication on the survival of cancer patients. We carried out an electrical literature search to identify the eligible studies published in PubMed, Web of Science and Embase together with the Chinese databases.
In total, 28 studies of 23 articles enrolling 3134 patients were included for this meta-analysis, of which 25 studies reported overall survival (OS), 4 studies evaluated recurrence-free survival (RFS) and 3 studies were related to disease-free survival (DFS). As a result, this meta-analysis revealed that up-regulation of miR-10b could confer an unfavorable factor for OS (HR=1.853, 95% CIs: 1.521-2.258, P<0.01) but not DFS (HR=1.309, 95% CIs: 0.699-2.453, P=0.4) or RFS (HR=2.692, 95% CIs: 0.877-8.265, P=0.084). Additionally, further analysis also suggested that overexpression of miR-10b predicted the shorter OS for the patient with different types of cancers, which contained lung cancer, breast cancer, glioma, colorectal cancer and gastric carcinoma. Subgroup analyses were also conducted according the region, sample size, system and miR-10b detection assay and statistical method.
This study shows that augmented expression of miR-10b strongly predicts poor prognosis for patients with cancers.
miR-10b 表达对癌症患者生存结果的影响仍存在争议。
进行了系统评价和荟萃分析，以确定其对癌症患者生存的影响。我们进行了电子文献检索，以确定在 PubMed、Web of Science 和 Embase 以及中文数据库中发表的合格研究。
共有 23 篇文章的 28 项研究纳入了这项荟萃分析，共 3134 名患者，其中 25 项研究报告了总生存率（OS），4 项研究评估了无复发生存率（RFS），3 项研究与无病生存率（DFS）有关。结果显示，miR-10b 的上调可导致 OS 不利（HR=1.853，95% CIs：1.521-2.258，P<0.01），但不能预测 DFS（HR=1.309，95% CIs：0.699-2.453，P=0.4）或 RFS（HR=2.692，95% CIs：0.877-8.265，P=0.084）。此外，进一步的分析还表明，miR-10b 的过表达预测了不同类型癌症患者的较短 OS，这些癌症包括肺癌、乳腺癌、神经胶质瘤、结直肠癌和胃癌。还根据地区、样本量、系统和 miR-10b 检测分析和统计方法进行了亚组分析。
本研究表明，miR-10b 的表达增加强烈预示着癌症患者预后不良。
